Loading...
Market
Which age group will have the highest uptake of FluMist nasal spray during the 2024-2025 flu season?
2
Resolution / Starting Odds
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%
Sales data segmented by age group from AstraZeneca and market research firms
Story
FDA Approves First-of-its-Kind At-Home FluMist Nasal Spray
Sep 20, 2024, 07:52 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self-administration or caregiver-administration. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. FluMist is licensed for individuals aged 2 to 49 and will be available through third-party pharmacies where users will complete a screening and eligibility assessment. The FDA's decision is part of a broader effort to expand consumer access to medicines and reduce healthcare costs and barriers.
View original story
Similar markets
2-18 years • 25%
19-29 years • 25%
30-49 years • 25%
All age groups equally • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-35 years • 25%
36-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
18-24 • 25%
25-34 • 25%
35-44 • 25%
45+ • 25%
Northeast • 25%
South • 25%
Midwest • 25%
West • 25%
Yes • 50%
No • 50%
Infants (0-1 year) • 25%
Children (2-12 years) • 25%
Teenagers (13-19 years) • 25%
Adults (20+ years) • 25%